PF-Atlas › Clinical Trials › NCT02742519

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

ivacaftor · Phase 3

Registry ID
NCT02742519
Phase
Phase 3
Status
Terminated
Drug / intervention
ivacaftor
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2016-05
Enrollment
14
Locations
6

About this trial

To evaluate the efficacy of ivacaftor treatment, as measured by lung clearance index (LCI), in subjects with cystic fibrosis (CF) who have a specified CF transmembrane conductance regulator (CFTR) gating mutation

View NCT02742519 on ClinicalTrials.gov →

Explore related

All ivacaftor trialsAll IPF trials

Related trials

ivacaftor — NCT02445053Ivacaftor — NCT00953706Ivacaftor — NCT01614457Ivacaftor — NCT01705145Ivacaftor — NCT02934698Ivacaftor — NCT03068312
Medical disclaimer. This page summarizes public trial data for NCT02742519 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.